ArriVent BioPharma Inc.
AVBP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.44B
Close$
$1.18
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.44 Billion |
|---|---|
| Enterprise Value | $1.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.32 |
| Beta | 1.3 |
| Outstanding Shares | 45,067,658 |
Return
| Return on Equity | -44.83% |
|---|---|
| Return on Assets | -41.58% |
| Return on Invested Capital | -34.69% |
Valuation & Multiples
| P/E Ratio | -8.74 |
|---|---|
| PEG | 26.7 |
| Price to Sales | - |
| Price to Book Ratio | 4.29 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.22 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.99
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 14, 2026
EPS Estimate
$-0.98
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 30.03% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.21%▼ 97.51% |
|---|---|
| Total Invested | $191.05M▼ 80.34% |
| Investors Holding | 42▼ 103.00% |
ESG Score
No data